Skip to main content
. 2020 Jan 30;34(7):1875–1884. doi: 10.1038/s41375-020-0711-6

Table 3.

Summary of second primary malignancies in the safety population.

D-Rd (n = 283) Rd (n = 281)
Total, n (%) 24 (8.5) 25 (8.9)
   Cutaneous/noninvasive 12 (4.2) 10 (3.6)
   Noncutaneous/invasive 8 (2.8) 11 (3.9)
   Hematologic 5 (1.8) 3 (1.1)

D-Rd daratumumab/lenalidomide/dexamethasone, Rd lenalidomide/dexamethasone.